Genetic variants in complement-related genes: potential implications for cancer risk and progression
Immunobiology · 2025
DOI: 10.1016/j.imbio.2025.153100 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunobiology, 2025. Verfasst von Jenny N Fung und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane, Australia. Electronic address: j.fung1@uq.edu.au. Hauptthemen laut MEDLINE: Neoplasms, Complement System Proteins, Genetic Predisposition to Disease, Genetic Variation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, Instituto de Salud Carlos III.
Abstract (Originalsprache)
The complement system is a critical component of the immune system, playing a significant role in pathogen defense and immune regulation. In cancer, it has a complex and dual role, either aiding in immune surveillance or contributing to tumor progression and immune evasion, depending on the specific context. While genetic and epigenetic regulation of complement-related genes has been studied in various diseases, its influence on cancer remains underexplored. This review focuses on how genetic variants in complement pathway genes may modulate cancer susceptibility, progression, and treatment outcomes. Genome-wide association studies (GWAS) have identified several key single nucleotide polymorphisms (SNPs) linked to complement genes, such as C3, C7, CFHR4 and ITGB2, which could influence immune responses and cancer development. Additionally, epigenetic modifications, such as DNA methylation, have been shown to regulate the expression of complement genes in cancer, adding further complexity to our understanding of their role in tumor immunity. Challenges remain in translating genetic and epigenetic insights into therapeutic strategies. The complex nature of cancer, tissue-specific complement regulation, and the difficulty in identifying reliable biomarkers complicate the development of targeted complement-based therapies for precision medicine. Therefore, future research combining genetic, genomic, and epigenomic data, along with functional genomics and proteomics, is needed to elucidate the potential roles of regulatory variants of complement genes in cancer. In addition to mechanistic studies, this information can be used to guide personalized treatment strategies for cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane, Australia. Electronic address: j.fung1@uq.edu.au.
- Program in Solid Tumors, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra's Health Research Institute (IdiSNA), Pamplona, Spain; Department of Biochemistry and G…
Förderung
- European Commission
- Instituto de Salud Carlos III
Zitieren
APA
Fung, J. N., & Pio, R. (2025). Genetic variants in complement-related genes: potential implications for cancer risk and progression. Immunobiology. https://doi.org/10.1016/j.imbio.2025.153100
Vancouver
Fung JN, Pio R. Genetic variants in complement-related genes: potential implications for cancer risk and progression. Immunobiology. 2025. doi:10.1016/j.imbio.2025.153100
BibTeX
@article{Fung2025,
author = {Fung, Jenny N and Pio, Ruben},
title = {Genetic variants in complement-related genes: potential implications for cancer risk and progression},
journal = {Immunobiology},
year = {2025},
doi = {10.1016/j.imbio.2025.153100}
}
EUVIMED